This novel IL-19 biomarker assay allowed us to demonstrate for the first time that decreases in serum IL-19 levels precede clinical responses in psoriasis when the therapeutic anti-IL-17A antibody ixekizumab is administered. This evidence concerns the gene IL17A and psoriasis.